Zoetis Inc. Q3 FY2026 results
$83.82+1.04%
Zoetis Inc. reported revenue of $2.39 billion, down 1.3% from a year earlier, net income of $591 million and diluted earnings per share of $1.44 against $1.63 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 5 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $2.39B | $2.42B | −1.3% |
| Gross profit | $1.69B | $1.73B | −1.9% |
| Gross margin | 70.8% | 71.2% | −0.4 pts |
| Operating income | $863.0M | $932.0M | −7.4% |
| Operating margin | 36.1% | 38.5% | −2.4 pts |
| Net income | $591.0M | $721.0M | −18.0% |
| Diluted EPS | $1.44 | $1.63 | −11.7% |
| Operating cash flow | $824.0M | $936.0M | −12.0% |
| Capital expenditure | $107.0M | $138.0M | −22.5% |
| Free cash flow | $717.0M | $798.0M | −10.2% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Dogs and Cats revenue | $1.5B | down 5.6% |
| Livestock revenue | $797.0M | up 6.8% |
| Parasiticides revenue | $576.0M | up 2.7% |
| Vaccines revenue | $540.0M | up 5.5% |
| Cattle revenue | $439.0M | up 5.8% |
| Dermatology revenue | $398.0M | down 15.7% |
| Anti-infectives revenue | $282.0M | down 1.7% |
| Pain and sedation revenue | $200.0M | unchanged |
| Animal health diagnostics revenue | $128.0M | up 14.3% |
| Swine revenue | $120.0M | up 3.4% |
| Poultry revenue | $108.0M | up 1.9% |
| Fish revenue | $98.0M | up 22.5% |
| Horses revenue | $73.0M | up 5.8% |
| Sheep and other revenue | $32.0M | up 10.3% |
| Contract manufacturing & human health revenue | $29.0M | up 11.5% |
| Companion Animal revenue | $585.0M | up 0.7% |
| U.S. revenue | $1.2B | down 5.7% |
| International revenue | $1.1B | up 3.9% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $2.39B | −1.3% | $1.44 |
| Q2 FY2026 | 30 Jun 2026 | $2.47B | −0.2% | $1.65 |
| Q1 FY2026 | 31 Mar 2026 | $2.26B | +2.9% | $1.42 |
| Q4 FY2025 | 31 Dec 2025 | $2.37B | +2.4% | $1.42 |
| Q3 FY2025 | 30 Sep 2025 | $2.42B | +1.4% | $1.63 |
| Q2 FY2025 | 30 Jun 2025 | $2.47B | +4.8% | $1.63 |
| Q1 FY2025 | 31 Mar 2025 | $2.20B | +0.4% | $1.34 |
| Q4 FY2024 | 31 Dec 2024 | $2.32B | +4.7% | $1.29 |
More on Zoetis Inc.: financial statements · revenue · earnings per share
ZTS's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
